BWAY
BrainsWay Ltd.
Healthcare · Medical Devices · NGM

$15.03
Close 2026-05-15
✓ ETHICAL PASS

MODERATE MOAT

HIGH
Data Confidence: 100%
Full financial profile available

Market Cap
$601.8M
Trailing P/E
83.50
Forward P/E
33.65
Rev Growth
+34.6%
Profit Margin
15.6%
ROE
12.6%
Analyst Target
$16.00
Recommendation
STRONG BUY

About BrainsWay Ltd.

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer’s disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson’s diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.

Opportunity Summary
Trading at $15, 12% above fair value of $13. Moderate competitive position. Passes all ethical screens. Ranks better than 82% of screened stocks.

Ethical Screen
Business Activity PASS
Debt Ratio (0.01%) PASS
Cash Ratio (0.11%) PASS
Receivables Ratio (0.00%) PASS
Revenue Ratio (0.00%) PASS
Overall PASS
Score Ethical: 95.6
Score Valuation: 36.5
Score Quality: 69.0
Score Combined: 56.0
Fair Value Est: $13.40 · Margin of Safety: -12.2% · Tier: FAIR VALUE

Full Analysis

Opportunity scores, earnings history, insider transactions, institutional holders, analyst consensus, and more.

Unlock with Membership

Opportunity Scores
Valuation31.8
Quality74.9
Cash Flow50.0
Moat50.0
Balance Sheet100.0
Debt Purity96.8
Liquid Purity67.8
Rev Purity100.0
Compliance89.2
Tier: SILVER · Score: 57.7 · Rank: #584

Earnings History (Last 8 Quarters)
Date EPS Est. Reported EPS Surprise %
2026-08-12 0.05 Pending
2026-05-13 0.05 0.06 +20.0%
2026-03-11 0.03 0.06 +155.4%
2025-11-11 0.02 0.02 -14.3%
2025-08-13 0.02 0.03 +53.9%
2025-05-13 0.01 0.01 -14.3%
2025-03-11 0.01 0.02 +100.0%
2024-11-12 0.01 0.01 +100.0%

Quarterly Financials
Period Revenue Net Income EBITDA Gross Profit Op. Income EPS
2026-03-31 $15.5M $2.3M $3.2M $11.7M $2.0M 0.06
2025-12-31 $14.5M $2.9M $3.3M $11.1M $1.9M 0.08
2025-09-30 $13.5M $1.6M $2.8M $10.2M $1.3M 0.04
2025-06-30 $12.6M $2.0M $3.3M $9.5M $578.0K 0.05
2025-03-31 $11.5M $1.1M $2.2M $8.6M $576.0K 0.03

Insider Transactions
No insider transaction data.
Top Institutional Holders
Holder Shares Value % Held
Valor Management LLC 5.3M $80.3M 0.1%
Masters Capital Management, LLC 1.6M $24.9M 0.0%
Acadian Asset Management. LLC 818.3K $12.4M 0.0%
Essex Investment Management Co LLC 618.6K $9.3M 0.0%
Renaissance Technologies, LLC 518.4K $7.8M 0.0%
Cresset Asset Management, LLC 314.9K $4.8M 0.0%
Y.D. More Investments Ltd 272.0K $4.1M 0.0%
SEI Investments Co 226.4K $3.4M 0.0%
ARK Investment Management, LLC 193.7K $2.9M 0.0%
Legato Capital Management LLC 192.2K $2.9M 0.0%

Analyst Recommendations
2 Months Ago
3
3 analysts

Last Month
3
3 analysts

Current
3
3 analysts

Strong Buy
Buy
Hold
Sell
Strong Sell

Additional Fundamentals
Enterprise Value
$524.4M
Price/Book
7.60
Beta
0.219
Analysts
3
Total Revenue (TTM)
$56.2M
Total Debt
$6.7M
Earnings Growth
+200.0%
Rec. Mean
1.00
Short Ratio
0.84
Short % Float
0.0%
Employees
129

Elite Intelligence

Trade Consideration with position sizing, convergence signals, and risk analysis. Available to Elite members.

Upgrade to Elite

Trade Consideration

The Opportunity
Score 56.0 (P87 — top 12.6% of scored tickers). Moderate Moat. Ethical PASS. 3 analysts at Strong Buy.
Price: $15.03 | Target: $16.00 (+6%) | Fair Value: $13.40 (+-11%)

Score
56

Moat
MODERATE

Conviction
Standard

Upside
+6%

The Fundamentals
Revenue Growth+34.6%
Profit Margin15.6%
ROE12.6%
Forward P/E33.6
Market Cap$601.8M

Earnings Track Record
Date Estimate Reported Surprise
2026-08-12 $0.05 Pending
2026-05-13 $0.05 $0.06 +20.0%
2026-03-11 $0.03 $0.06 +155.4%
2025-11-11 $0.02 $0.02 -14.3%
2025-08-13 $0.02 $0.03 +53.9%
2025-05-13 $0.01 $0.01 -14.3%
Position Sizing Scenarios
Stop: $12.78 (-15%) | Entry: $15.03
Shares Cost Profit to Target R:R
To Consensus ($16.00, 3 analysts)
10 $150.30 +$9.70 (6%) 0.4R
50 $751.50 +$48.50 (6%) 0.4R
100 $1,503.00 +$97.00 (6%) 0.4R
To Fair Value ($13.40)
10 $150.30 +$-16.30 (-11%) -0.7R
50 $751.50 +$-81.50 (-11%) -0.7R
100 $1,503.00 +$-163.00 (-11%) -0.7R
Risk Factors
  • Valuation stretched on forward earnings

The Verdict
BrainsWay Ltd. passes all ethical screens, holds a moderate competitive moat, and is growing revenue at +34.6%.

Quantitative Grade

A single score combining all analytical layers below. A is strongest, D is weakest.

B
Quant Score
55.6
Risk Grade
LOW_RISK
Layers
8
Quality: HIGH_SORTINO,STRONG_EARNINGS_DRIFT

Risk Profile

How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.

VaR 95%
-4.4%
worst expected daily loss, 19 in 20 days
CVaR 95%
-6.1%
avg loss on the worst 5% of days
Annual Volatility
Sortino Ratio
3.16
above 1.0 is good
Max Drawdown
-32.2%
Worst Day

Forward Outlook

Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.

30d Prob Up
90d Prob Up
Median Return 30d
Liquidity Score
65
Liquidity Grade
LIQUID

Trend & Momentum

What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?

Kalman Trend
Trend Strength
Momentum Signal
HMM Regime
RSI Signal

Technical Signals

Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.

MA Crossover
ABOVE_200
Bollinger Position
LOWER_HALF
Beta
Relative Volume
0.5x
Short Interest

Financial Health

Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.

Altman Z-Score
below 1.81 = distress zone

Piotroski F-Score

Earnings Beat Rate
75.0%
Earnings Consistency

Correlations

These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.

Most Correlated
Ticker Correlation
Q 0.380
KLAR 0.376
IWM 0.369
CSQ 0.363
BTX 0.363
Inverse Correlated
Ticker Correlation
GIS -0.175
FAREAST.KL -0.169
BAES.L -0.161
KR -0.154
ED -0.148

Seasonality

Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.

Best Day
Wednesday
Worst Day
Friday
Best Month
Aug
Worst Month
Feb
Fri-Mon Effect
-0.9077288331421609

Earnings Drift

After this company beats earnings, does the price keep going up? Drift tracks post-earnings momentum.

Avg Drift After Beat
+5.3%
Beat Drift Positive %
80.0%
Consistency

Momentum Rankings

How does this ticker’s recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.

1M Return
-2.9%
3M Return
+30.2%
6M Return
+119.2%
12M Return
+204.7%
Momentum Rank
#267
Momentum Signal
STRONG_UP

Related Tickers

Similar in Healthcare

INCY — Incyte CRMD — CorMedix Inc. ✓ UHS — Universal Health Services ✓ FENC — Fennec Pharmaceuticals Inc. ✓ REGN — Regeneron Pharmaceuticals ✓

Also in TE500

NEM — Newmont ✓ NU — Nu Holdings Ltd. PTC — PTC Inc. ✓ SBNY — Signature Bank EXE — Expand Energy ✓
Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry Indicators Options Calendar Composites Boycott Tracker Convergence Screener Fed Tracker Explore All Is It Halal? Earnings Calendar Dividend Screener Country Guides Glossary Join Free →

Get our weekly market brief free.